April 10, 2026 (MLN): Highnoon Laboratories Limited has placed a detailed account of its related party transactions for shareholder consideration ahead of its Annual General Meeting scheduled for April 30, 2026, highlighting extensive financial dealings with subsidiaries and associated companies during 2025.

The company’s disclosures show significant business activity with its wholly owned subsidiary Curexa Health (Private) Limited, where sales reached Rs526.6 million during 2025, alongside purchases of Rs231.7m.

Additional financial flows included royalty income of Rs4.48m, sale of fixed assets worth Rs38.3m, and receipts totaling Rs220.8m, the on PSX revealed today.

Highnoon also extended financial support to its subsidiary through a Rs425m loan and made an equity investment of Rs125m, showing continued capital backing.

Interest income on the loan stood at Rs7.59m, while receivables amounting to Rs150.7m were adjusted against outstanding loan balances.

Transactions with associate Route 2 Health (Private) Limited also remained notable, with net sales recorded at Rs115.3m.

The company earned royalty income of Rs6.35m and posted receipts of Rs127m. Dividend flows from this associate amounted to Rs9.52m.

Meanwhile, investment-linked returns from Pharmatec Investments Limited contributed significantly, with dividends declared at Rs176.6m during 2025.

The disclosures further outline contributions to staff retirement and welfare funds exceeding Rs88m, indicated ongoing commitments to employee benefit structures.

All transactions were carried out in the ordinary course of business and underwent review by the board and audit committee, with shareholders set to evaluate and ratify these dealings.

The move aligns with regulatory requirements, ensuring transparency in financial relationships within the group.

The scale and diversity of these transactions underline Highnoon’s integrated operational structure, where subsidiaries and associated entities play a central role in revenue generation, capital deployment, and overall financial performance.

Copyright